D&D Pharmatech Inc.
A GLP-1 peptide-based drug developer with an oral obesity treatment partnered with Pfizer and pipelines for MASH, Parkinson's, and Alzheimer's disease.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2014 and listed on KOSDAQ in 2024, D&D Pharmatech develops innovative therapies for metabolic and neurodegenerative diseases based on GLP-1 and other peptide technologies. Its core pipeline includes an oral obesity treatment partnered with Pfizer, MASH (metabolic dysfunction-associated steatohepatitis) treatment DD01, Parkinson's and Alzheimer's disease treatment NLY01, and fibrotic disease treatment TLY012, leveraging drug delivery technologies such as PEGylation and its ORALINK platform for converting injectables to oral formulations. Through its U.S. subsidiary Neuraly Inc. it develops PET imaging biomarkers, Valted Seq, Inc. is building the single-cell genomic analysis platform SCADE, and it holds a 15% stake in Z-Alpha Therapeutics, classified as an affiliate, which is developing next-generation alpha radiation cancer therapies.
R&D and key agreements
Source: DART corporate disclosure경구용 비만치료제 · 비만 · GLP-1-based, partnered with Pfizer (formerly Metsera, acquired by Pfizer Nov 2025)
DD01 · MASH(대사이상 관련 지방간염)
NLY01 · 파킨슨병, 알츠하이머병
TLY012 · 섬유화질환
PET 이미징 바이오마커 개발 · Conducted by subsidiary Neuraly Inc.
SCADE · 퇴행성 뇌질환 · AI-based single-cell genomic analysis platform built by Valted Seq, Inc.
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition